Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,716.09
(
0.25%
)
US TECH 100
24,127.20
(
0.47%
)
Dow Jones
46,993.26
(
0.10%
)
Brent Oil
98.66
(
-1.98%
)
Bitcoin
74,212.23
(
0.36%
)
News Focus
News Focus
Post# of 257253
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

masterlongevity

Send PM Follow Ignore
Followers 24
Posts 2597
Boards Moderated 0
Alias Born 01/07/2004

masterlongevity

Re: None

Tuesday, 01/12/2010 8:17:22 PM

Tuesday, January 12, 2010 8:17:22 PM

Post# of 257253
From Biogen SEC Filing - sales of TYSABRI® (natalizumab) during 2009 were approximately $1,059.2 million

Biogen Idec Inc. announced today that sales of TYSABRI® (natalizumab) during 2009 were approximately $1,059.2 million, comprised of approximately $508.5 million of sales in the United States and approximately $550.7 million of sales in the rest of the world.


Dew, wasn't there a survey about tysabri sales??
Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

Trade Smarter with Thousands

Leverage decades of market experience shared openly.

Join Now